Bexmarilimab Plus Azacitidine for TP53-Mutated High-Risk MDS: BEXMAB Study Update

Myelofibrosis Year in Review With Dr. Raajit Rampal

Tailoring Myelofibrosis Clinical Trial End Points

LINKER-MM2 Trial Insights in Myeloma With Meletios-Athanasios Dimopoulos, MD

Research Powering the Next Era of CLL Therapy

The Role of XPO1 Inhibition From Early to Advanced Myeloma

Jean-Marie Michot, MD, Shares Olympia-3 Insights on Odronextamab Plus Chemotherapy in DLBCL

Dr. Robert Orlowski Shares Linvoseltamab Benefits in Frontline Multiple Myeloma

Low Risk MDS 1L Care: Patient EPO Levels, Ring Sideroblast Presence in Therapy Choice

Low Risk MDS 1L Care: Parameters for Deciding When, or If to Begin Therapy

Modern Targeted Treatment Strategies in CLL

BTK Inhibitors and the Genomic Shift in CLL

High-Risk DLBCL Beyond R-CHOP

AML on the Frontlines: Turning Trial Data Into Real-World Care

Why Toxicity and Time Matter in Blood Cancer Care

The Fight Against Myeloid Malignancies: Early Warning Signs and Emerging Innovations

Patients and Clinicians Share Real-World Myeloma Treatment Experiences at ASH 2025 Panel Event

Low Risk MDS 1L Care: Current Landscape, Trends in Management

SURPASS Trial to Investigate Promising Monoclonal Antibody for Hemophagocytic Lymphohistiocytosis

Rapcabtagene Autoleucel: Promising New CD19 CAR T-Cell Therapy for High-Risk LBCL

CLL Year in Review: Zanubrutinib, Venetoclax, and the Shifting Treatment Landscape

Determining Cardiovascular Risk for Patients With CLL Receiving BTKis

Managing Cardiovascular Toxicities in Patients With CLL Receiving BTKis

Dr. Prithviraj Bose Outlines Novel Combinations in JAKi-Naïve Myelofibrosis

Redefining End Points in Myelofibrosis Clinical Trials

Treating Patients With JAKi-Naïve Myelofibrosis

Richter Transformation of CLL: Promising Therapy Directions and Key Elements of Care

Richter Transformation of CLL: Progress in Understanding Disease Etiology, Clinical Trials

Longer Survival With Better Quality of Life: CAR-T for Multiple Myeloma

Optimizing EO Peptide Combination in Patients With FL and MZL

Peptide Vaccine Shows Promise in Relapsed or Refractory FL and MZL

Quadruplet Versus Triplet Therapy for Multiple Myeloma: Dr. Jesús San-Miguel Shares Key Trial Data

MRD Negativity Associated With Favorable Patient-Reported Outcomes in Patients With Multiple Myeloma

STEM Trial: Cevostamab Consolidation Sustains MRD Negativity After CAR-T in Multiple Myeloma

Should Clinicians Use FLT3 Inhibitor Maintenance in FLT3-ITD AML? MRD Helps Inform the Decision

Novel SWIFT-Seq Blood Test Transforms Multiple Myeloma Diagnosis and Prognosis

CLL Awareness Day: Relapsed CLL in Focus

Unpacking Controversies in CLL Treatment

Balancing Survival and Long-Term Wellness in Patients With Lymphoma

What Are the Outstanding Needs Today in Multiple Myeloma Care, Clinical Research?

Multicenter Study Grows Experience Optimizing Teclistamab for MM in Older Adults

SENTRY Trials: Dr. Nikolai Podoltsev on Treatment Doublets for JAK inhibitor-Naïve Myelofibrosis

Ide-Cel versus Cilta-Cel for Refractory MM: What Is the Bottom Line for Patients?

Modern Myelofibrosis Care: The Clinical Trial Landscape

Modern Myelofibrosis Care: What Is the Overall Approach to Diagnosis, Treatment?

Symptom Monitoring After Hospitalization in Cancer Care

New Standards in Ph+ and High-Risk ALL

Advances in CLL Monitoring and Prognosis

Improving Cure Rates in AML with Targeted Combinations

Which Second-Generation JAK Inhibitors Take the Spotlight in 2025?

Luspatercept in First-Line MDS Care: Real-World Data and the Real-World Clinical Experience

Luspatercept for MDS Management: What Data and Clinical Experience Are Still Needed?

Biologic Synergy in Focus: Liso-cel and NKTR-255 in Advanced LBCL

COMMANDS Trial Data Update: Do the New Data Change Luspatercept’s Place in First-Line MDS Care?

MDS 1L Management: How Do EPO Levels, Ring Sideroblast Status Influence Treatment Decisions?

Myeloma Now: Insights and Innovations

Patient Monitoring to Change After FDA CAR T-Cell Label Update Approval

Ongoing Debates in the Management of Smoldering Myeloma

TAG in BPDCN: Dr. Anthony Stein Shares Phase 1/2 Insights

Navigating Relapsed Myeloma: Expert Panel Tackles Unanswered Questions